ASH Conference 2020 Highlights on CAR-T Therapies for Relapsed/Refractory Multiple Myeloma
A look at select abstracts from the 62nd American Society of Hematology Annual Meeting focusing on clinical trials investigating CAR-T therapies for patients with relapsed/refractory multiple myeloma. Various CAR-T agents represent the potential for further expansion of the range of options to facilitate increased survival and improvements in quality of life in this patient population.
